Fluorthanatrace F-18 clinical trials
How each study uses fluorthanatrace F-18 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the fluorthanatrace F-18 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2023 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 7
Abramson Cancer Center at Penn Medicine (5) · Washington University School of Medicine (1) · Heather Wachtel (1)
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test fluorthanatrace F-18.
- Dec 2026In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and ParagangliomaEarly Phase 1 · Heather Wachtel
- Jul 2027Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast CancerPhase 1 · Abramson Cancer Center at Penn Medicine
- Jul 2027FTT PET/CT in Metastatic Prostate CancerEarly Phase 1 · Abramson Cancer Center at Penn Medicine
- Sep 2027FTT PET/CT in Pancreatic Neuroendocrine TumorsPhase 1 · Abramson Cancer Center at Penn Medicine
Studies
Open first, then newest update. How each study uses fluorthanatrace F-18 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- [18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)RecruitingPhase 2Washington University School of MedicineNCT07723651Written as 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-oneHow we know
- FTT PET/CT in Metastatic Prostate CancerRecruitingEarly Phase 1Abramson Cancer Center at Penn MedicineNCT05242744Written as [18F]FluorThanatraceHow we know
- In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and ParagangliomaRecruitingEarly Phase 1Heather WachtelNCT05636540Written as [18F]FluorThanatrace ([18F]FTT)How we know
- FTT PET/CT in Pancreatic Neuroendocrine TumorsRecruitingPhase 1Abramson Cancer Center at Penn MedicineNCT07114939Written as [18F]FluorThanatraceHow we know
- Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CTActive, not recruitingPhase 1Abramson Cancer Center at Penn MedicineNCT02637934Written as [18F]FluorThanatraceHow we know
- Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast CancerActive, not recruitingPhase 1Abramson Cancer Center at Penn MedicineNCT03083288Written as [18F]FluorThanatraceHow we know
- In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic CancerTerminatedEarly Phase 1Abramson Cancer Center at Penn MedicineNCT03492164Written as [18F]FluorThanatrace ([18F]FTT)How we know
What changed recently
From the registry's own updates since Oct 23, 2026.
Started recruiting1
Codes
What other systems call fluorthanatrace F-18 · ClinicalTrials.gg INT015840
- UNII (FDA) 9B8U3WZ84WFLUORTHANATRACE F-18One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 9B8U3WZ84W | FLUORTHANATRACE F-18 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.